Medical Learning Institute, Inc.

MLI provides continuing education designed to impact the practice behavior of the healthcare team and has achieved Joint Accreditation with Commendation!

[Medical Learning Institute, Inc. @mlieducation]

Is your lenalidomide backbone providing your patients with Multiple Myeloma long-term success? Hear what @khancology  has to say in the first episode of our new reelCE series on #RRMM. 

Watch the full series and collect CE credit at https://t.co/QRdoSL0KP9

#MMSM #MedEd #multiplemyeloma #hemonc

[Medical Learning Institute, Inc. @mlieducation]

@Bushramalik1215 @szusmani The full series is now available at https://t.co/J51F5mfgVR! 🤗

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

IMiDs & CELMoDs both hit cereblon, but they are not the same class. Let's talk about what puts CELMoDs in their own lane for treating multiple myeloma #RRMM.

Watch the full reelCE series from @mlieducation & claim CE credit at https://t.co/QsX3Kq0BKs. cc @szusmani @khancology

#reelCE #mmsm #multiplemyeloma #MedEd

[Medical Learning Institute, Inc. @mlieducation]

What if earning CE fit right into your social media feed? Start earning CE credit with our upcoming #reelCE series on multiple myeloma, featuring Drs. Rahul Banerjee, Adeel Khan, and Saad Usmani - coming soon!

Follow along & stay tuned!

#RRMM #mmsm #multiplemyeloma #meded #reelCE

[Saad Z. Usmani MD MBA FASCO 🇺🇸🇵🇰 @szusmani]

Finding time for CE isn't always easy. That's why I'm excited to be part of an upcoming reelCE™ series from @mlieducation - free, accredited CE delivered in quick, bite-sized videos designed for busy clinicians. Coming soon. Stay tuned!

#mmsm #multiplemyeloma #meded #reelCE

[Adeel Khan MD MPH MS @khancology]

As clinicians, finding time for CE isn't always easy. The next reelCE™ series from @mlieducation is almost here - free, accredited CE delivered in quick, digestible videos you can watch anytime, anywhere. Follow along for the launch! #mmsm #multiplemyeloma #MedEd #RRMM

[Medical Learning Institute, Inc. @mlieducation]

Live from #ADCES26 » Game Plan for Basal Insulin: From Initiation to Adjustment https://t.co/DAxgt55E2J

[Medical Learning Institute, Inc. @mlieducation]

Basal insulin isn’t the problem - the approach is. If your patients with T2D are above goal, it’s time to refine your strategy.

Save your spot for a live dinner symposium this Sunday at #ADCES26 (or join via livestream) & learn strategies to help CDCESs & BC-ADMs personalize insulin, optimize titration & boost adherence 👉https://t.co/b47lGulrU3

@ADCESdiabetes
#CDCES #diabetes #diabetescare

[Medical Learning Institute, Inc. @mlieducation]

https://t.co/cmYliP5toP

[Medical Learning Institute, Inc. @mlieducation]

That's a wrap on #ESMOGI26 - what a week for #GICancer research! The take home message - multimodal systemic and local therapy is the future for oncological treatment. Expert #HCC faculty share their full analyses on our on-demand #CME webinar soon. Join the waitlist: https://t.co/xf6hkUjyYX

#HCC #LiverCancer

[Medical Learning Institute, Inc. @mlieducation]

Dr. Arndt Vogel stopped by yesterday to chat with us about some of the data that he found most exciting at #ESMOGI26

#HCC #gicancer #livercancer #pancreaticcancer

[Medical Learning Institute, Inc. @mlieducation]

Michel P Ducreaux pondered the future of #HCC at #ESMOGI26's closing remarks on this sunny Saturday morning in Munich - discussing the future for combinations of systemic and local therapies in #GICancer treatment

[Medical Learning Institute, Inc. @mlieducation]

Our time at #ESMOGI26 is quickly coming to an end - many talks have highlighted the importance of evaluating disease burden prior to #GICancer treatment. Full expert analysis on-demand redeemable for CME credit. Pre-register: https://t.co/xf6hkUjyYX

#HCC #GIOncology #MedEd #PersonalizedMedicine

[Medical Learning Institute, Inc. @mlieducation]

A 4-year update from the CHIEF French Cohort - the longest prospective real-world follow-up of AtezoBev - has confirmed durable benefit with a survival plateau near 29% at 48 months, with some responses enabling conversion to curative-intent treatment! 

#HCC #LiverCancer #MedEd #ESMOGI26

[Medical Learning Institute, Inc. @mlieducation]

Dr. Stephen Chan shared some of the emerging modalities of local treatment in #LiverCancer, including histotripsy and irreversible electroporation but notes that the data on these techniques still needs to be matured before it can be widely adopted in clinical practice

#ESMOGI26 #CME #MedTwitter #LiverTwitter #HCC

[Medical Learning Institute, Inc. @mlieducation]

Yesterday, @ma5RN shared a key 2026 BCLC #HCC staging system update: CUSE framework turns unavoidable doubt into a shared, iterative process to improve treatment satisfaction for patients, personalized medicine, and an #AI-assisted decision making system to help reduce practitioner burden

#ESMOGI26 #LiverCancer #personalizedmedicine #LiverTwitter #GIOncology #MedTwitter

[Medical Learning Institute, Inc. @mlieducation]

Day 2 at #ESMOGI26 included news about technology innovations, SIERRA and EMERALD updated safety data, and a lively poster session. Dr. Stephen Chan's full SIERRA breakdown will be coming in our post-congress webinar. Pre-register: https://t.co/xf6hkUjyYX

#HCC #LiverCancer #LiverTwitter #MedTwitter #GIoncology

[Medical Learning Institute, Inc. @mlieducation]

Update to the phase 3b SIERRA study from @LorenzaRimassa - STRIDE showed a manageable safety profile and meaningful efficacy with poor prognosis in #uHCC, results consistent with prior evidence which support STRIDE as first line SOC for a broad patient population.

#ESMOGI2026 #HCC #LiverCancer #LiverTwitter #GIoncology #MedEd

[Medical Learning Institute, Inc. @mlieducation]

This morning, Leonardo da Fonseca shared some of the challenges of downstaging in #HCC in Child-Pugh B patients - defining safe biologic limits while avoiding futile procedures, preserving equitable organ allocations, and balancing immunotherapy related risks.

#ESMOGI2026 #LiverCancer #LiverTwitter #GIoncology #MedTwitter

[Medical Learning Institute, Inc. @mlieducation]

Dr. Bruno Sangro presented the final OS and updated safety data from EMERALD-1: TACE+D followed by D+B did not prolong OS vs TACE (HR 1.1; OS maturity, 68%), TACE+D followed by D did not prolong OS vs TACE (HR 0.93; OS maturity, 66%). Safety was manageable and consistent with known profiles.

#ESMOGI2026 #HCC #LiverTwitter #GIoncology #MedTwitter